Answers are grounded in this paper and cite their sources.
Comparative characterization of CD19 CAR T-cell products reveals enhancements in automated manufacturing systems.
Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of relapsed or refractory hematological malignancies. However, conventional CAR T-cell manufacturing is labor-intensive and costly, faces challenges in scaling production and carries a potential risk of contamination, supporting the adoption of closed, automated systems for point-of-care manufacturing. Here, we performed a functional comparative characterization of CD19 CAR T-cell products generated through an extended manufacturing cycle on the Wukong (SinoBiocan, China) and KunLun (XinBio, China) automated platforms using a single leukapheresis product. Both platforms generated viable T-cell products with high post-selection purity and measurable CAR expression. On day 10, the KunLun-produced CAR T product yielded 5.11 × 108 cells (99.4% CD3+), with 23.9% CAR expression (approximately 1.22 × 108 CAR+ cells), a balanced CD4:CD8 ratio (approximately 1:1) and >90% cell viability. The Wukong product yielded 2.64 × 108 cells (98.3% CD3+), with 18.5% CAR expression (approximately 5.0 × 107 CAR+ cells) and a CD4-skewed subset distribution, also with >90% viability. In a fluorescence-based coculture assay using the human Burkitt’s lymphoma-derived cell line Raji-mKate2 as a target, both products demonstrated CD19-specific cytotoxicity. KunLun-derived CAR T cells exhibited higher cytolysis rates across the tested effector-to-target ratios, reaching 78% specific lysis at 10:1 after 24 hours. Together, these data support the feasibility of closed, automated point-of-care CAR T-cell manufacturing and indicate that platform design and process implementation can influence final yield, CAR+ cell output, product composition and functional activity. Since the current analysis was performed using leukapheresis material from a single donor, future studies using additional donors, replicate runs and deeper product profiling are needed to identify parameters that best predict the clinical performance of CAR T-cell products. PEER REVIEWED ARTICLE **Peer reviewers:** Prof. Ancha Baranova, School of Systems Biology, George Mason University, Fairfax, Virginia, USA One anonymous peer reviewer Received on November 21, 2025; accepted after peer review on March 30, 2026; published online on April 09, 2026.
No takes yet. Share an insight, caveat, or question.
Rybachuk et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: